Article

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.

Division of Geriatric Psychiatry, Ambulatory Care Pavilion, Zucker-Hillside Hospital, Glen Oaks, NY, USA.
Neuropsychiatric Disease and Treatment (Impact Factor: 2). 01/2010; 6:47-58.
Source: PubMed

ABSTRACT Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient's previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson's disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence.

0 Bookmarks
 · 
142 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dovepress 1363 R e v I e w open access to scientific and medical research Open Access Full Text Article http://dx.doi.org/10.2147/CIA.S63942 Abstract: The use of atypical antipsychotic drugs in the elderly has become wider and wider in recent years; in fact, these agents have novel receptor binding profiles, good efficacy with regard to negative symptoms, and reduced extrapyramidal symptoms. However, in recent years, the use of both conventional and atypical antipsychotics has been widely debated for concerns about their safety in elderly patients affected with dementia and the possible risks for stroke and sudden death. A MEDLINE search was made using the words elderly, atypical antipsychotics, use, schizophrenia, psychosis, mood disorders, dementia, behavioral disorders, and adverse events. Some personal studies were also considered. This paper reports the receptor binding profiles and the main mechanism of action of these drugs, together with their main use in psychiatry and the possible adverse events in elderly people.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Risperidone is the only antipsychotic currently licensed for the behavioural and psychological symptoms of dementia. Drs Rachis and Shankar describe the case of an elderly man with Alzheimer's disease who developed behavioural symptoms and delusions, who responded well to aripiprazole after treatment with risperidone failed.
    Progress in Neurology and Psychiatry 05/2014; 18(3).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of atypical antipsychotic drugs in the elderly has become wider and wider in recent years; in fact, these agents have novel receptor binding profiles, good efficacy with regard to negative symptoms, and reduced extrapyramidal symptoms. However, in recent years, the use of both conventional and atypical antipsychotics has been widely debated for concerns about their safety in elderly patients affected with dementia and the possible risks for stroke and sudden death. A MEDLINE search was made using the words elderly, atypical antipsychotics, use, schizophrenia, psychosis, mood disorders, dementia, behavioral disorders, and adverse events. Some personal studies were also considered. This paper reports the receptor binding profiles and the main mechanism of action of these drugs, together with their main use in psychiatry and the possible adverse events in elderly people.
    Clinical Interventions in Aging 01/2014; 9:1363-1373. · 2.65 Impact Factor

Full-text (2 Sources)

Download
60 Downloads
Available from
May 26, 2014